A detailed history of Schwartz Investment Counsel Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Schwartz Investment Counsel Inc holds 1,000 shares of VRTX stock, worth $502,450. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$502,450
Previous $468,000 0.64%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Oct 17, 2023

SELL
$338.18 - $362.46 $338,180 - $362,460
-1,000 Reduced 50.0%
1,000 $347,000
Q2 2022

Aug 11, 2022

SELL
$234.96 - $292.55 $58,740 - $73,137
-250 Reduced 11.11%
2,000 $564,000
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $97,355 - $122,897
550 Added 32.35%
2,250 $494,000
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $108,833 - $121,794
600 Added 54.55%
1,700 $308,000
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $227,722 - $265,441
1,100 New
1,100 $236,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Schwartz Investment Counsel Inc Portfolio

Follow Schwartz Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schwartz Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Schwartz Investment Counsel Inc with notifications on news.